Britain posed to ban hybrid embryos

Jan 05, 2007

Patients "desperate for therapy" would be denied potential treatment if Britain outlaws human-animal embryos, scientists said.

By proposing to prohibit the fusion of human DNA with animal eggs, scientists said ministers are barring access to a powerful medical research tool, The Times of London said Friday. The technique produces embryos that are 99.5 percent human and is aimed to address the shortage of human eggs for stem cell research.

The proposal was released last month. It won't become law for at least a year, but scientists said it already affected research. Two groups wanting to use the technique applied to the Human Fertilization and Embryology Authority for licenses, which are expected to be denied.

British Public Health Minister Caroline Flint said the decision followed public consultation in which most participants opposed the technique. Scientists said only 535 commented.

"There are hundreds of thousands of patients in Britain with degenerative neurological conditions," Chris Shaw, King's College London, who is researching motor neuron disease, told The Times. "We can use these cell lines to study them, and to see if drugs are going to be effective. To shut that down is a real affront to patients who are desperate for therapy."

Copyright 2007 by United Press International

Explore further: Amgen misses 1Q views as higher costs cut profit

add to favorites email to friend print save as pdf

Related Stories

Designing robots that can keep secrets

Mar 05, 2014

Humanoid robots are not just the stuff of science fiction: these computing devices are likely to be walking around our streets in the next decade.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Man among first in US to get 'bionic eye' (Update)

A degenerative eye disease slowly robbed Roger Pontz of his vision. Diagnosed with retinitis pigmentosa as a teenager, Pontz has been almost completely blind for years. Now, thanks to a high-tech procedure ...